Patients should be reassured that whilst awareness of potential complications is important, serious adverse effects remain uncommon
Excessive use, such as binge drinking (four drinks for women, five for men in one sitting), exacerbates these risks
Assays were performed following the manufacturers protocol for each kit
Common adverse reactions to Wegovy include nausea (reported in up to 44% of patients during clinical trials according to the MHRA SmPC), vomiting, diarrhoea, constipation, and abdominal discomfort
Since its FDA approval in 2017, Regeneron and Sanofis Dupixent was touted to be a major breakthrough for patients with AD, with industry analysts dubbing it to be life changing. Since then, Regeneron has secured approvals in additional indications, most notably asthma